Literature DB >> 2941280

Penetration of ciprofloxacin into bronchial secretions.

E Bergogne-Bérézin, G Berthelot, P Even, M Stern, P Reynaud.   

Abstract

The penetration of ciprofloxacin into bronchial secretions was evaluated in 21 patients after a single oral dose of 500 mg of ciprofloxacin. Ten successive serum samples were collected in the interval 0-12 h after administration, and bronchial samples were taken 2, 3, 4 and 6 h after administration. Concentrations were measured in all samples using a standard microbiological assay. The results showed that the kinetics in serum did not differ from those determined in previous studies, a peak level of 2.2 +/- 1.3 mg/l being achieved at 2 h followed by a slow decrease of the levels to 0.6 +/- 0.4 mg/l at 6 h. The bronchial concentrations reached about 0.5 mg/l at 2 h and remained stable until 6 h, ranging between 0.5 and 0.8 mg/l. The ratio between simultaneous bronchial and serum levels ranged from 0.19 at 2 h to 0.95 at 6 h. These data indicate that ciprofloxacin might be suitable for treatment of severe respiratory infections, especially pneumonia caused by Pseudomonas aeruginosa, since the MICs of ciprofloxacin for most bacteria involved in bronchopulmonary infections are very low and tissue diffusion of the drug in the respiratory tract is good.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941280     DOI: 10.1007/bf02013986

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  7 in total

1.  Pharmacokinetics of three oral formulations of ciprofloxacin.

Authors:  R L Davis; J R Koup; J Williams-Warren; A Weber; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  Susceptibility of Legionella spp. to quinolone derivatives and related organic acids.

Authors:  G Ruckdeschel; W Ehret; A Ahl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

Review 5.  Pharmacokinetics of tissue penetration of antibiotics.

Authors:  T Bergan
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

6.  Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study.

Authors:  B I Davies; F P Maesen; J P Teengs
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

7.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

  7 in total
  15 in total

1.  Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

Authors:  E Pérez-Trallero; J M Garcia-Arenzana; J A Jimenez; A Peris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

2.  Calculation of the antibiotic level in the lung tissue and bronchial secretion with an oral controlled-release dosage form.

Authors:  M Saïdna; E M Ouriemchi; J M Vergnaud
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

3.  Single and multiple dose pharmacokinetics of ciprofloxacin.

Authors:  U Ullmann; W Giebel; A Dalhoff; P Koeppe
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

4.  Penetration of antibiotics into the respiratory tract.

Authors:  J Symonds
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-09

5.  The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration.

Authors:  M Dan; K Torossian; D Weissberg; R Kitzes
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Dangers of oral fluoroquinolone treatment in community acquired upper respiratory tract infections.

Authors:  R J Körner; D S Reeves; A P MacGowan
Journal:  BMJ       Date:  1994-01-15

7.  Antibiotic penetration into lung tissues.

Authors:  D Honeybourne
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

8.  Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.

Authors:  P Saux; C Martin; M N Mallet; L Papazian; B Bruguerolle; P De Micco; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Inappropriate breast secretions of possible bacterial etiology in the parous nonpuerperal female.

Authors:  J J Freeman; R H Altieri; A H Freeman; T Kuo; F Sardinha; C C Buckingham; J J Sklar; K Dyroff; A Floyd
Journal:  J Natl Med Assoc       Date:  1994-03       Impact factor: 1.798

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.